title: Antibiotic allergy in cystic fibrosis.
abstract: Allergic reactions to antibiotics are more common in cystic fibrosis (CF) than in the general population. This in part is due to the improving survival in adults with CF and the increased use of high dose intravenous antibiotics. While some are immediate anaphylaxis type (IgE mediated) reactions, the majority are late onset and may have non-specific features such as rash and fever. Piperacillin has consistently been found to have the highest rate of reported reactions (30-50%). There is a low risk of cross reactions between penicillins and other non-beta-lactam classes of antibiotics in penicillin skin prick positive patients. Carbapenems should only be used with extreme caution in patients with positive skin prick tests to penicillin. However, aztreonam can be used safely in patients who are penicillin allergic with positive skin prick reactions. The aminoglycosides are a relatively uncommon cause of allergic reactions, but patients who react to one member of the family may cross react with other aminoglycosides. Desensitisation relies on the incremental introduction of small quantities of the allergen and has been used for penicillins, ceftazidime, tobramycin and ciprofloxacin and must be repeated before each course. Personalized cards should be regularly updated for patients who develop allergic reactions. Written instructions on the emergency treatment of allergic reactions should be provided to patients self-administering intravenous antibiotics at home. Further research is required to identify risk factors and predictors for antibiotic allergy.
authors.affiliation: Transplant Unit, Papworth NHS Trust Hospital, UK.
authors.forename: J S
authors.initials: JS
authors.lastname: Parmar
authors.forename: S
authors.initials: S
authors.lastname: Nasser
mesh_terms: D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D003550:Cystic Fibrosis / Q000150:complications* / Q000188:drug therapy; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000209:etiology / Q000628:therapy; D004347:Drug Interactions; D006801:Humans; D012307:Risk Factors
chemical_list: D000900:Anti-Bacterial Agents